单克隆抗体在感染SARS-CoV-2的儿童中的安全性。
Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection.
作者信息
Romani Lorenza, Calò Carducci Francesca Ippolita, Chiurchiù Sara, Cursi Laura, De Luca Maia, Di Giuseppe Martina, Krzysztofiak Andrzej, Lancella Laura, Palma Paolo, Vallesi Leonardo, Corsetti Tiziana, Campana Andrea, Nicastri Emanuele, Rossi Paolo, Bernardi Stefania
机构信息
Immunology and Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Research Unit of Congenital and Perinatal Infections, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
出版信息
Children (Basel). 2022 Mar 7;9(3):369. doi: 10.3390/children9030369.
Abstract
Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-CoV-2 infection in children aged from 24 days to 18 years old.
摘要
用于治疗新冠肺炎的单克隆抗体疗法在成人中已被频繁使用，然而，关于单克隆抗体治疗对感染新冠肺炎的儿科患者的安全性或有效性的数据却很少。我们报告了我们使用单克隆抗体治疗24天至18岁儿童感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的经验。
相似文献
1
Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection.单克隆抗体在感染SARS-CoV-2的儿童中的安全性。
Children (Basel). 2022 Mar 7;9(3):369. doi: 10.3390/children9030369.
2
Serum IgG levels in children 6 months after SARS-CoV-2 infection and comparison with adults.儿童感染 SARS-CoV-2 6 个月后的血清 IgG 水平及与成人的比较。
Eur J Pediatr. 2021 Nov;180(11):3335-3342. doi: 10.1007/s00431-021-04124-w. Epub 2021 May 22.
3
Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.针对严重急性呼吸系统综合征冠状病毒 2 刺突受体结合蛋白的中和单克隆抗体 CT-P59 的安全性、病毒学疗效和药代动力学：两项在健康个体和轻度严重急性呼吸系统综合征冠状病毒 2 感染患者中进行的随机、安慰剂对照、I 期研究。
Clin Ther. 2021 Oct;43(10):1706-1727. doi: 10.1016/j.clinthera.2021.08.009. Epub 2021 Aug 23.
4
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.靶向刺突受体结合域的中和单克隆抗体赋予叙利亚仓鼠免受 SARS-CoV-2 感染的 Fc 受体非依赖性保护。
mBio. 2021 Oct 26;12(5):e0239521. doi: 10.1128/mBio.02395-21. Epub 2021 Sep 14.
5
Use of Monoclonal Antibody to Treat COVID-19 in Children and Adolescents: Risk of Abuse of Prescription and Exacerbation of Health Inequalities.使用单克隆抗体治疗儿童和青少年的新冠肺炎：处方滥用风险与健康不平等加剧
Pharmaceuticals (Basel). 2021 Jul 15;14(7):673. doi: 10.3390/ph14070673.
6
Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies.多发性骨髓瘤及其他接受单克隆抗体治疗的血液系统恶性肿瘤患者的新型冠状病毒2型血清学检测评估
Diagnostics (Basel). 2020 Nov 24;10(12):992. doi: 10.3390/diagnostics10120992.
7
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection.用于治疗和预防 SARS-CoV-2 感染的中和单克隆抗体。
New Microbiol. 2021 Jul;44(3):135-144.
8
The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies.SARS-CoV-2 感染的免疫学、潜在的基于抗体的治疗方法和疫苗接种策略。
Expert Rev Anti Infect Ther. 2021 Jul;19(7):899-910. doi: 10.1080/14787210.2020.1863144. Epub 2020 Dec 30.
9
Monoclonal antibody therapy in COVID-19.COVID-19 中的单克隆抗体疗法。
J Biol Regul Homeost Agents. 2021 Mar-Apr;35(2):423-427. doi: 10.23812/Conti_Edit_35_2_1.
10
Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.在德国一家三级保健医院，针对有发生重症 COVID-19 高风险的患者，使用单克隆抗体疗法治疗医院获得性 SARS-CoV-2 感染的经验。
Infection. 2021 Dec;49(6):1313-1318. doi: 10.1007/s15010-021-01657-y. Epub 2021 Jul 9.
引用本文的文献
1
[Current Status of Passive Immunization Against COVID in Respiratory Patients].[呼吸道疾病患者中新冠被动免疫的现状]
Open Respir Arch. 2025 Jan 17;7(2):100398. doi: 10.1016/j.opresp.2025.100398. eCollection 2025 Apr-Jun.
2
Use of Remdesivir in children with COVID-19: report of an Italian multicenter study.瑞德西韦在儿童 COVID-19 中的应用：一项意大利多中心研究报告。
Ital J Pediatr. 2024 Feb 27;50(1):32. doi: 10.1186/s13052-024-01606-z.
3
Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce.儿童和青少年 COVID-19 预防和管理指南：儿科传染病学会儿科 COVID-19 治疗工作组的共识声明。
J Pediatric Infect Dis Soc. 2024 Mar 19;13(3):159-185. doi: 10.1093/jpids/piad116.
4
SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis.SARS-CoV-2 中和抗体 bebtelovimab - 系统范围界定审查和荟萃分析。
Front Immunol. 2023 Aug 28;14:1100263. doi: 10.3389/fimmu.2023.1100263. eCollection 2023.
5
A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia.奥密克戎变异株再感染 1 例：对 1 例伴 B 细胞急性淋巴细胞白血病的儿科患者产生显著免疫增强作用
BMC Infect Dis. 2023 Mar 7;23(1):133. doi: 10.1186/s12879-023-08111-4.
6
Early Treatments of Fragile Children with COVID-19-Results of CLEVER (Children COVID Early Treatment), a Retrospective, Observational Study.COVID-19 脆弱儿童的早期治疗-CLEVER（儿童 COVID 早期治疗）的回顾性观察研究结果。
Viruses. 2023 Jan 10;15(1):192. doi: 10.3390/v15010192.
7
SARS-CoV-2 infection and treatment in a cohort of patients with inborn errors of immunity.一组先天性免疫缺陷患者中的新型冠状病毒2型感染与治疗
Pediatr Allergy Immunol. 2022 Aug;33(8):e13833. doi: 10.1111/pai.13833.
本文引用的文献
1
Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement.儿科患者使用抗 SARS-CoV-2 单克隆抗体治疗的资格标准：意大利多学会共识声明。
Ital J Pediatr. 2022 Jan 12;48(1):7. doi: 10.1186/s13052-021-01187-1.
2
COVID-19 mental health impact among children with early brain injury and associated conditions.早期脑损伤及相关病症儿童中 COVID-19 对心理健康的影响。
Child Neuropsychol. 2022 Jul;28(5):627-648. doi: 10.1080/09297049.2021.1998407. Epub 2021 Nov 15.
3
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
4
Treatment of children with COVID-19: update of the Italian Society of Pediatric Infectious Diseases position paper.新型冠状病毒肺炎患儿的治疗：意大利儿科学会立场文件更新
Ital J Pediatr. 2021 Oct 7;47(1):199. doi: 10.1186/s13052-021-01132-2.
5
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.卡西瑞维单抗-英夫西单抗治疗与轻至中度新型冠状病毒肺炎高危患者的住院率降低相关。
EClinicalMedicine. 2021 Oct;40:101102. doi: 10.1016/j.eclinm.2021.101102. Epub 2021 Aug 30.
6
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.巴尼韦单抗/依特司韦单抗在轻中度 COVID-19 中的应用。
N Engl J Med. 2021 Oct 7;385(15):1382-1392. doi: 10.1056/NEJMoa2102685. Epub 2021 Jul 14.
7
Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients.COVID-19 儿科患者单抗治疗的安全性和耐受性。
Pediatr Infect Dis J. 2021 Dec 1;40(12):e507-e509. doi: 10.1097/INF.0000000000003263.
8
The emerging SARS-CoV-2 variants of concern.新出现的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）关注变体。
Ther Adv Infect Dis. 2021 Jun 18;8:20499361211024372. doi: 10.1177/20499361211024372. eCollection 2021 Jan-Dec.
9
Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19.常见变异性免疫缺陷病、T 细胞对 SARS-CoV-2 疫苗的反应与慢性 COVID-19 的风险。
J Allergy Clin Immunol Pract. 2021 Oct;9(10):3575-3583. doi: 10.1016/j.jaip.2021.06.019. Epub 2021 Jun 25.
10
Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies.感染 SARS-CoV-2 后产生中和抗体的儿童的病毒学和免疫学特征。
Cell Rep. 2021 Mar 16;34(11):108852. doi: 10.1016/j.celrep.2021.108852.
Zotero 插件